SEHK:867Pharmaceuticals
What China Medical System Holdings (SEHK:867)'s Stroke Drug NDA Acceptance Means For Shareholders
On 11 December 2025, China Medical System Holdings announced that China’s National Medical Products Administration accepted the New Drug Application for Y-3 (Loberamisal) for Injection, a Class 1 innovative brain cytoprotectant for acute ischemic stroke based on PSD-95-nNOS and MPO targets.
This first-in-class, multi-target therapy addresses both stroke damage and post-stroke mood complications, positioning the company more firmly in China’s large and complex cerebrovascular disease...